Cogent Biosciences
COGT
69 hedge funds and large institutions have $303M invested in Cogent Biosciences in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 17 closing their positions.
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
29% more capital inflows, than outflows
Capital inflows: $60.2M | Capital outflows: $46.7M
2.46% more ownership
Funds ownership: 90.22% → 92.68% (+2.5%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 69 → 69 (0)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 2 |
Millennium Management
New York
|
+$6.93M |
| 3 |
Janus Henderson Group
London,
|
+$5.34M |
| 4 |
Commodore Capital
New York
|
+$4.9M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.32M |
| 2 |
OrbiMed
New York
|
-$7.36M |
| 3 |
Consonance Capital Management
New York
|
-$6.85M |
| 4 |
Samsara BioCapital
Palo Alto,
California
|
-$6.61M |
| 5 |
ACM
Altium Capital Management
New York
|
-$4.86M |
COGT Hedge Fund Activity: Q1 2021 in Review
69 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2021, worth a combined $303M — down 20% from $377M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new COGT positions and 17 closed out — a net gain of 1 holder — while 27 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $12.3M. The largest seller was Morgan Stanley, cutting an estimated $8.32M.
- 69 institutional investors held Cogent Biosciences (COGT) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $303M of Cogent Biosciences stock for Q1 2021, down 20% quarter-over-quarter.
- 18 funds opened new Cogent Biosciences positions in Q1 2021 and 17 closed out, a net change of +1 holder.
- The largest Cogent Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $12.3M added.
- The largest Cogent Biosciences seller in Q1 2021 was Morgan Stanley, an estimated $8.32M sold.
Based on aggregated 13F filings for Q1 2021.